ClinVar Miner

Submissions for variant NM_000022.4(ADA):c.890C>A (p.Pro297Gln)

gnomAD frequency: 0.00003  dbSNP: rs121908718
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000059115 SCV001413001 pathogenic Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency 2024-01-26 criteria provided, single submitter clinical testing This sequence change replaces proline, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 297 of the ADA protein (p.Pro297Gln). This variant is present in population databases (rs121908718, gnomAD 0.02%). This missense change has been observed in individual(s) with partial adenosine deaminase (ADA) deficiency (PMID: 2166947, 2783588). ClinVar contains an entry for this variant (Variation ID: 1961). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ADA protein function with a negative predictive value of 80%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on ADA function (PMID: 2166947). This variant disrupts the p.Pro297 amino acid residue in ADA. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV002260959 SCV002541684 uncertain significance not provided 2021-09-01 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002307351 SCV002600454 uncertain significance not specified 2022-10-12 criteria provided, single submitter clinical testing Variant summary: ADA c.890C>A (p.Pro297Gln) results in a non-conservative amino acid change located in the Adenosine deaminase domain (IPR001365) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251492 control chromosomes (gnomAD). c.890C>A has been reported in the literature in the homozygous and compound heterozygous states in two partially ADA deficient children, identified through Newborn Screening (Hirschhorn_1989, Hirschhorn_1990). A later report by the same authors (Hirschhorn_1995) stated that up to that date, the children had not presented with immunodeficiency. GeneReviews defines partial ADA deficiency as a benign condition which is compatible with normal immune function (PMID 20301656). These report(s) do not provide unequivocal conclusions about association of the variant with Severe Combined Immunodeficiency. Experimental evidence evaluating an impact on protein function demonstrated the variant to have normal electrophoretic mobility and abnormal heat stability, with ADA activity measured at 56% in homozygous lymphoid cells (Hirschhorn_1989, Hirschhorn_1990). A ClinVar submitter (evaluation after 2014) cites the variant as likely pathogenic, while another ClinVar submitter (evaluation after 2014) cites it as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
GeneDx RCV002260959 SCV003930939 pathogenic not provided 2023-05-09 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate a damaging effect as transfection of the mutant cDNA into heterologous cells resulted in expression of a heat-labile ADA of normal electrophoretic mobility, properties exhibited by the ADA in the patients' cells (Hirschhorn et al., 1989); Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 9225964, 2783588, 21898656, 24772956, 20493397, 2166947, 31589614, 34975878, 23645737)
Baylor Genetics RCV000059115 SCV004216604 likely pathogenic Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency 2023-10-30 criteria provided, single submitter clinical testing
OMIM RCV000002038 SCV000022196 pathogenic Partial adenosine deaminase deficiency 1989-02-01 no assertion criteria provided literature only
UniProtKB/Swiss-Prot RCV000059115 SCV000090643 not provided Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency no assertion provided not provided

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.